Role of SIV and HIV Env cytoplasmic tail in pathogenesis and protective immunity

SIV和HIV Env胞质尾在发病机制和保护性免疫中的作用

基本信息

  • 批准号:
    10092084
  • 负责人:
  • 金额:
    $ 76.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-03-15 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

Project Summary In pathogenic HIV and SIV infection innate and adaptive immune responses fail to control viral replication and, coupled with persisting immune activation, lead to the progressive depletion of CD4+/CCR5+ T cells and AIDS. Numerous HIV and SIV vaccines have also failed to elicit immune responses that can broadly prevent or control infection. Although immune control of HIV and SIV can occur, the determinants are unclear, as is the ability to induce these responses with vaccines. There is thus, an urgent need to identify and understand immune responses that can broadly prevent or control HIV/SIV infection and to elicit these responses with vaccines. A model is described in which deletion of a Gly and Tyr within a highly conserved trafficking motif in the SIVmac239 envelope (Env) cytoplasmic tail produces a virus (∆GY) that in pigtail macaques (PTM) replicates acutely to wildtype levels, but becomes highly controlled by cellular immune responses in the absence of neutralizing antibodies. Remarkably, animals that control ∆GY infection are able to prevent or control diverse challenges with homologous SIVmac239, heterologous SIVsmE660 and SHIV-SF162P3N, which are all highly pathogenic in PTM. Recent studies of mutations acquired in rare ∆GY animals that progressed to AIDS and of viral evolution in PTM depleted of CD8 cells prior to ∆GY infection, have implicated the loss of polarized trafficking of Env in infected cells as a driver for ∆GY's altered pathogenesis. These findings have suggested that Env trafficking plays a critical dual role in promoting both cell-cell spread of virus in tissues and in evading CD8 cellular immune responses. As these events are mediated by virologic and immunologic synapses, respectively, we hypothesize that this motif is critical in vivo in promoting infectivity and modulating viral susceptibility to cellular immune attack. Findings with the ∆GY model suggest that disrupting this motif can not only alter pathogenesis but also enable potent and broadly protective immune responses to occur. This testable hypothesis and its implications for vaccines will be assessed in 4 Aims: 1) To identify the immune correlates of ∆GY control and responses that are shared during control of diverse challenges; 2) To provide a mechanistic understanding of this model by characterizing differences in virologic and immunologic synapses during ∆GY and SIVmac239 infection; 3) To assess the impact of alterations in Env trafficking on immunogenicity in the context of a novel mRNA vaccine; and 4) To extend findings for the immunomodulatory role of this conserved trafficking motif in SIV to an HIV-1 Env. These highly novel observations are positioned to provide new insights into protective immunity for the SIV and HIV vaccine fields.
项目摘要 在致病性HIV和SIV感染中,先天性和适应性免疫应答不能控制病毒复制, 再加上持续的免疫激活,导致CD 4 +/CCR 5 + T细胞的进行性耗竭和AIDS。 许多HIV和SIV疫苗也未能引起可以广泛预防或治疗的免疫应答。 控制感染。虽然可以对HIV和SIV进行免疫控制,但其决定因素尚不清楚, 疫苗诱导这些反应的能力。因此,迫切需要确定和了解 免疫反应,可以广泛地预防或控制HIV/SIV感染,并引发这些反应, 疫苗。描述了一种模型,其中缺失高度保守的运输基序内的Gly和Tyr, SIVmac 239包膜(Env)胞质尾区产生病毒(CMV戈伊),其在猪尾猕猴(PTM)中 急性复制到野生型水平,但变得高度控制的细胞免疫反应, 缺乏中和抗体。值得注意的是,控制猪戈伊感染的动物能够预防或 用同源SIVmac 239、异源SIVsmE 660和SHIV-SF 162 P3 N控制不同的攻击, 这些都是PTM的高致病性。最近的研究表明,在罕见的哺乳戈伊动物中获得的突变, 进展为AIDS和在PTM中的病毒进化,PTM中的CD 8细胞在HIV戈伊感染之前耗尽,已经暗示了 感染细胞中Env的极化运输的丧失是Escherichia戈伊改变的发病机制的驱动因素。这些 研究结果表明,Env运输在促进病毒的细胞间传播方面起着关键的双重作用, 在组织和逃避CD 8细胞免疫应答中。由于这些事件是由病毒学和 免疫突触,我们假设这个基序在体内促进感染性是至关重要的, 调节病毒对细胞免疫攻击的易感性。研究结果表明,干扰戈伊模型 这种基序不仅可以改变发病机制,而且还可以使有效的和广泛的保护性免疫应答, 发生.这一可检验的假设及其对疫苗的影响将在4个目标中进行评估:1) 确定免疫相关性的控制和反应,在控制不同的戈伊, 挑战; 2)通过表征病毒学差异来提供对该模型的机制性理解 在EMP戈伊和SIVmac 239感染过程中, 在新型mRNA疫苗的背景下运输免疫原性;以及4)为了扩展 这种保守的运输基序在SIV到HIV-1 Env中的免疫调节作用。这些非常新颖的 这些观察定位于为SIV和HIV疫苗领域的保护性免疫提供新的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James A Hoxie其他文献

James A Hoxie的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James A Hoxie', 18)}}的其他基金

Targeted interventions to reduce or eliminate the SIV reservoir in a novel model of elite control
有针对性的干预措施,以减少或消除新型精英控制模型中的 SIV 储存库
  • 批准号:
    10013657
  • 财政年份:
    2020
  • 资助金额:
    $ 76.19万
  • 项目类别:
Targeted interventions to reduce or eliminate the SIV reservoir in a novel model of elite control
有针对性的干预措施,以减少或消除新型精英控制模型中的 SIV 储存库
  • 批准号:
    10371090
  • 财政年份:
    2020
  • 资助金额:
    $ 76.19万
  • 项目类别:
Non-CD4 tropic SIV: Enhancing CD4 T-cell help in antiviral immune responses
非 CD4 tropic SIV:增强 CD4 T 细胞有助于抗病毒免疫反应
  • 批准号:
    8732145
  • 财政年份:
    2014
  • 资助金额:
    $ 76.19万
  • 项目类别:
CONTROL OF AN SIVMAC239 TRANSMEMBRANE MUTANT IN PIGTAIL MACAQUES
尾猴中 SIVMAC239 跨膜突变体的控制
  • 批准号:
    8358143
  • 财政年份:
    2011
  • 资助金额:
    $ 76.19万
  • 项目类别:
PATHOGENESIS OF AN ATTENUATED SIVMAC239 IN RHESUS AND PIGTAIL MACAQUES
减毒 SIVMAC239 在恒河猴和尾猴中的发病机制
  • 批准号:
    8358095
  • 财政年份:
    2011
  • 资助金额:
    $ 76.19万
  • 项目类别:
Optimizing HIV Env immuogens for T and B cell vaccine responses
优化 HIV 包膜免疫原以实现 T 和 B 细胞疫苗反应
  • 批准号:
    8505364
  • 财政年份:
    2010
  • 资助金额:
    $ 76.19万
  • 项目类别:
Optimizing HIV Env immuogens for T and B cell vaccine responses
优化 HIV 包膜免疫原以实现 T 和 B 细胞疫苗反应
  • 批准号:
    8091276
  • 财政年份:
    2010
  • 资助金额:
    $ 76.19万
  • 项目类别:
Optimizing HIV Env immuogens for T and B cell vaccine responses
优化 HIV 包膜免疫原以实现 T 和 B 细胞疫苗反应
  • 批准号:
    7988637
  • 财政年份:
    2010
  • 资助金额:
    $ 76.19万
  • 项目类别:
Optimizing HIV Env immuogens for T and B cell vaccine responses
优化 HIV 包膜免疫原以实现 T 和 B 细胞疫苗反应
  • 批准号:
    8300199
  • 财政年份:
    2010
  • 资助金额:
    $ 76.19万
  • 项目类别:
PATHOGENIC DETERMINANTS OF THE SIV ENVELOPE TRANSMEMBRANE CYTOPLASMIC DOMAIN
SIV 包膜跨膜细胞质域的致病决定因素
  • 批准号:
    8173001
  • 财政年份:
    2010
  • 资助金额:
    $ 76.19万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 76.19万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了